Our early-stage discovery and research expertise has generated multiple compounds and programs that target key pathways in cancer and metabolic diseases. We have established collaborations with leading pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Genentech, Inc. (a wholly-owned member of the Roche Group), GlaxoSmithKline, Sanofi, Merck (known as MSD outside of the United States and Canada) and Daiichi-Sankyo Company Limited, for a variety of our compounds and programs. Pursuant to these collaborations, we have out-licensed compounds or programs to a partner for further development and commercialization, generally have no further unfunded cost obligations related to such compounds or programs and may be entitled to receive research funding, milestones and royalties or a share of profits from commercialization. Working with these leaders in the fields of cancer and metabolic disease ensures that our innovative compounds are being developed effectively.